Your browser doesn't support javascript.
loading
Prediction of the Optimal Dosing Regimen Using a Mathematical Model of Tumor Uptake for Immunocytokine-Based Cancer Immunotherapy.
Ribba, Benjamin; Boetsch, Christophe; Nayak, Tapan; Grimm, Hans Peter; Charo, Jehad; Evers, Stefan; Klein, Christian; Tessier, Jean; Charoin, Jean Eric; Phipps, Alex; Pisa, Pavel; Teichgräber, Volker.
Afiliación
  • Ribba B; Pharmaceutical Sciences, Roche Pharmaceutical Research & Early Development, Roche Innovation Center, Basel, Switzerland. benjamin.ribba@roche.com.
  • Boetsch C; Pharmaceutical Sciences, Roche Pharmaceutical Research & Early Development, Roche Innovation Center, Basel, Switzerland.
  • Nayak T; Translational Imaging Science Oncology, Roche Pharmaceutical Research & Early Development, Roche Innovation Center, Basel, Switzerland.
  • Grimm HP; Pharmaceutical Sciences, Roche Pharmaceutical Research & Early Development, Roche Innovation Center, Basel, Switzerland.
  • Charo J; Translational Medicine Oncology, Roche Pharmaceutical Research & Early Development, Roche Innovation Center, Zurich, Switzerland.
  • Evers S; Translational Medicine Oncology, Roche Pharmaceutical Research & Early Development, Roche Innovation Center, Zurich, Switzerland.
  • Klein C; Discovery Oncology, Roche Pharmaceutical Research & Early Development, Roche Innovation Center, Zurich, Switzerland.
  • Tessier J; Translational Imaging Science Oncology, Roche Pharmaceutical Research & Early Development, Roche Innovation Center, Basel, Switzerland.
  • Charoin JE; Pharmaceutical Sciences, Roche Pharmaceutical Research & Early Development, Roche Innovation Center, Basel, Switzerland.
  • Phipps A; Pharmaceutical Sciences, Roche Pharmaceutical Research & Early Development, Roche Innovation Center, Welwyn, England.
  • Pisa P; Translational Medicine Oncology, Roche Pharmaceutical Research & Early Development, Roche Innovation Center, Zurich, Switzerland.
  • Teichgräber V; Translational Medicine Oncology, Roche Pharmaceutical Research & Early Development, Roche Innovation Center, Zurich, Switzerland.
Clin Cancer Res ; 24(14): 3325-3333, 2018 07 15.
Article en En | MEDLINE | ID: mdl-29463551
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Citocinas / Factores Inmunológicos / Modelos Teóricos / Neoplasias Tipo de estudio: Diagnostic_studies / Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Clin Cancer Res Asunto de la revista: NEOPLASIAS Año: 2018 Tipo del documento: Article País de afiliación: Suiza
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Citocinas / Factores Inmunológicos / Modelos Teóricos / Neoplasias Tipo de estudio: Diagnostic_studies / Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Clin Cancer Res Asunto de la revista: NEOPLASIAS Año: 2018 Tipo del documento: Article País de afiliación: Suiza